LISATA THERAP.INC.DL-001 (F:8NE) — Market Cap & Net Worth
Market Cap & Net Worth: LISATA THERAP.INC.DL-001 (8NE)
LISATA THERAP.INC.DL-001 (F:8NE) has a market capitalization of $16.56 Million (€14.16 Million) as of May 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #25583 globally and #2208 in its home market, demonstrating a -8.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LISATA THERAP.INC.DL-001's stock price €2.58 by its total outstanding shares 8820733 (8.82 Million).
LISATA THERAP.INC.DL-001 Market Cap History: 2015 to 2026
LISATA THERAP.INC.DL-001's market capitalization history from 2015 to 2026. Data shows change from $1.53 Billion to $26.61 Million (-33.07% CAGR).
LISATA THERAP.INC.DL-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LISATA THERAP.INC.DL-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 8NE by Market Capitalization
Companies near LISATA THERAP.INC.DL-001 in the global market cap rankings as of May 5, 2026.
Key companies related to LISATA THERAP.INC.DL-001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
LISATA THERAP.INC.DL-001 Historical Marketcap From 2015 to 2026
Between 2015 and today, LISATA THERAP.INC.DL-001's market cap moved from $1.53 Billion to $ 26.61 Million, with a yearly change of -33.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €26.61 Million | +64.33% |
| 2025 | €16.19 Million | -43.93% |
| 2024 | €28.87 Million | +12.90% |
| 2023 | €25.57 Million | +14.81% |
| 2022 | €22.27 Million | -80.00% |
| 2021 | €111.37 Million | -38.46% |
| 2020 | €180.98 Million | -40.61% |
| 2019 | €304.73 Million | -34.11% |
| 2018 | €462.51 Million | +4.36% |
| 2017 | €443.17 Million | +11.00% |
| 2016 | €399.24 Million | -73.85% |
| 2015 | €1.53 Billion | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of LISATA THERAP.INC.DL-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.56 Million USD |
| MoneyControl | $16.56 Million USD |
| MarketWatch | $16.56 Million USD |
| marketcap.company | $16.56 Million USD |
| Reuters | $16.56 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more